London (PRWEB) September 24, 2013
Medicines for bowel inflammation - you explore R&D and potential sales
What's the future for treating inflammatory bowel diseases (IBD)? Visiongain's updated report gives you revenue predictions from 2013, helping you stay ahead. There you find financial results, R&D trends, opportunities, and potential revenues.
In that work you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess emerging technologies. Try our new report.
Analysis of what shapes the IBD drugs industry and determines its potential
Discover what the future holds for agents treating inflammatory bowel disorders: Crohn's disease and ulcerative colitis. Read on, then, to explore that drug industry and see what its future market could be worth.
Forecasts to 2023 and other data show you commercial potentials
Besides revenue forecasting, our new work shows recent results, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and developments (R&D). You also get 74 tables, 34 charts, and three interviews.
You know how hard it can be to find data. All that searching. Now, though, you can stay ahead in knowledge for IBD medicine, benefiting your research, analyses, and decisions.
Avoid falling behind. Also save time. Finding information you need just got easier. There, in our study, you hear what's happening and see where the money lies.
The following sections, then, show what you get in our new investigation.
Prospects for the world market and submarkets for IBD medications
Our report shows revenue to 2023 for the overall world IBD drug market. It also shows you individual forecasts for five submarkets:
Copyright©2012 Vocus, Inc.
All rights reserved